Comparison of the Efficacy & Safety of Resusix With FP24 in Patients With Acquired Coagulopathy

Inclusion Criteria: * SBP 90-150 mm Hg * acquired coagulopathy due to hepatic disease * INR \>1.4 * Order for 1-4 units of plasma for active bleeding or prophylaxis for bleeding prior to surgery or invasive procedure * Written informed consent * MELD score: 25 or less (1st cohort), 35 or less (2nd cohort) Exclusion Criteria: * Pregnant women * Incarcerated patients * Life expectancy less than 72 hours * Severe bleeding at time of enrollment * HIV, sepsis, intracranial bleeding, congenital disorder, anti-phospholipid antibody syndrome or known lupus anticoagulant antibodies * Receipt of plasma products, coagulation factor concentrates or anti-platelets within 3 days of enrollment * Specific factor inhibitor activity or history of hypersensitivity to plasma-derived products * Receipt of iv heparin within 24 hours of enrollment * Use of a continuous infusion of an intravenous vasoactive medication * Thrombocytopenia * BMI greater than or equal to 40 kg/m2 * Participation in another clinical trial within 30 days of enrollment and received investigational product that may impact safety or efficacy of this study * West Haven Hepatic Encephalopathy Grade 3 or 4 (cohort 1) and Grade 4 (cohort 2)